Modified IL-8 Inhibits Neutrophil Infiltration via GAG Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for lung inflammatory diseases such as COPD, cystic fibrosis, and severe asthma are largely ineffective in addressing neutrophilic infiltration and inflammation, with traditional glucocorticosteroids failing to attenuate inflammation, highlighting the need for new anti-inflammatory strategies targeting CXCL8-mediated lung inflammation.
Innovation Solution
A modified interleukin 8 (IL-8) with increased GAG binding affinity and inhibited or down-regulated GPCR activity is used as an inhalant to prevent or treat lung inflammation by competing with wild-type IL-8 for GAG binding sites and reducing neutrophil activation, thereby addressing the key chemokine involved in neutrophil mobilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional glucocorticosteroids are used to treat lung inflammation, then symptomatic care is provided, but anti-inflammatory activity is largely ineffective
Solution Approach 1:
The patent modifies the amino acid sequence of IL-8 to change its binding parameters - specifically increasing affinity for GAG while decreasing affinity for CXCR1/2 receptors. This parameter change transforms IL-8 from a pro-inflammatory agent into an anti-inflammatory agent that can effectively block neutrophil recruitment without activating receptors
Solution Approach 2:
The modified IL-8 acts as an intermediary substance that binds to GAG on the endothelial cell surface, physically blocking wild-type IL-8 from reaching its receptors. This intermediary approach prevents the harmful interaction between CXCL8 and CXCR1/2 without requiring direct receptor antagonism
2Reliability
If wild-type IL-8 is present in the lung, then neutrophil mobilization occurs, but this leads to increased neutrophilic infiltration and inflammation
Solution Approach 1:
The patent takes the harmful pro-inflammatory properties of wild-type IL-8 and converts them into beneficial anti-inflammatory properties through site-directed mutagenesis. The modified IL-8 retains GAG binding capability but loses receptor binding, transforming a neutrophil attractant into a neutrophil recruitment blocker
Solution Approach 2:
Instead of trying to block IL-8 activity indirectly through receptor antagonists or upstream inhibitors, the patent inverts the approach by creating an IL-8 variant that naturally binds to the same GAG sites but produces the opposite effect - preventing rather than promoting neutrophil recruitment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified IL-8 effectively reduces neutrophil infiltration and inflammation in lung tissues, demonstrating significant anti-inflammatory activity comparable to or exceeding that of standard treatments like dexamethasone in animal models of COPD and acute lung inflammation, offering a novel approach for managing neutrophilic lung diseases.
Implementation Method 1
modified interleukin 8 (IL-8, CXCL8) having increased GAG binding affinity
Data Source
AI summary
The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.